Innovation drives ResMed sales

Sales by obstructive sleep apnea treatment pioneer ResMed (ASX: RMD) powered ahead 13 per cent in the final quarter of 2018-19, driven by the release of new products. The Sydney company announced revenue up 13 per cent for the final quarter ended June 30 to $1.02 billion, bringing full year revenue to $3.8 billion. Net…